Drugs / A-005
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07442149 | Apr → Dec 2024 | — | Alumis Inc | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-12-19 | Alumis Inc | Results Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005 alumis.com ↗
In the clinical trial, A-005 was well tolerated with no serious adverse events reported. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-12-19 | Alumis Inc | Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005 alumis.com ↗ |
| 2024-04-30 | Alumis Inc | Alumis Announces First Participant Dosed in Phase 1 Clinical Trial of CNS Penetrant Allosteric TYK2 Inhibitor A-005 alumis.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | A-005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07442149 ↗ |
| Route | Oral | “orally-administered A-005” NCT07442149 ↗ |